Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinibs - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 un 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Latvija - latviešu - Zāļu valsts aģentūra

lfb biomedicaments, france - cilvēka villebranda faktors - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 1000 sv

Latvija - latviešu - Zāļu valsts aģentūra

baxalta innovations gmbh, austria - cilvēka ix koagulācijas faktors - pulveris un šķīdinātājs injekciju/infūziju šķīduma pagatavošanai - 1200 sv

Latvija - latviešu - Zāļu valsts aģentūra

octapharma (ip) sprl, belgium - cilvēka ix koagulācijas faktors - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 1000 sv

Latvija - latviešu - Zāļu valsts aģentūra

octapharma (ip) sprl, belgium - cilvēka ix koagulācijas faktors - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 500 sv

Latvija - latviešu - Zāļu valsts aģentūra

lfb biomedicaments, france - cilvēka villebranda faktors - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 500 sv

Latvija - latviešu - Zāļu valsts aģentūra

lfb biomedicaments, france - cilvēka villebranda faktors - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 2000 sv

Latvija - latviešu - Zāļu valsts aģentūra

baxalta innovations gmbh, austria - cilvēka ix koagulācijas faktors - pulveris un šķīdinātājs injekciju/infūziju šķīduma pagatavošanai - 600 sv

Latvija - latviešu - Zāļu valsts aģentūra

aspen pharma trading ltd., ireland - nadroparīna kalcija sāls - Šķīdums injekcijām - 3800 anti-xa sv/0,4 ml

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiski līdzekļi - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. papildinformāciju par cilvēka epidermas augšanas faktora 2 receptora (her2) statusu, lūdzu, skatiet 5. sadaļā. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. sīkāku informāciju par her2 statusu, lūdzu, skatiet 5. sadaļā. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).